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Abstract 
Purpose: To review current therapeutic efficacy of artemether-lumefantrine (AL) for the treatment of 
uncomplicated Plasmodium falciparum malaria in patients in Enugu State, Nigeria.  
Methods: One hundred and fifty four malaria patients from three different Local Government Areas 
(LGA) of Enugu State, southeastern Nigeria, that fulfilled the inclusion criteria were recruited through 
rapid diagnostic testing and blood film microscopy. The patients received a 3-day complete dose of AL 
treatment; they were monitored and 3 mL of blood in EDTA bottle was sampled on days 0, 3, 7, 14 and 
28. The samples were evaluated by real-time polymerase chain reaction (RT-PCR) for identification and 
quantification of Plasmodium falciparum. Clinical and parasitological responses were recorded and 
analyzed statistically. 
Results: There was significant decrease (p > 0.002) in patient’s temperature (from 40 to 37 ºC) from 
day 0 to day 28. There was significant decrease (p < 0.001) between parasite mean density on day 0 
and the values on days 3,7,14 and 28, with high prevalence of delayed parasite clearance. There was 
no early treatment failure, while 4 (3.4 %), 30 (25.4 %), and 84 (75.1 %) had late clinical failure, late 
parasitological response and adequate clinical and parasitological response, respectively.  
Conclusion:  Artemether – lumefantrine combination therapy reduced fever in malaria patients but 
failed to totally clear parasitemia density, indicating its reduced therapeutic efficacy in Enugu State, 
Nigeria. 
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Widespread resistance of malaria parasites to 
commonly available anti-malarial drugs has 
necessitated countries to review and deploy new 
anti-malarial drug policies to ensure effective 
case management [1]. In 2005 Nigerian National 
Antimalarial Treatment Policy (NNATP) adopted 
artemether-lumefantrine (AL) as the first line drug 
for treatment of uncomplicated malaria in Nigeria. 
Although, several studies [2-4] done with children 
of 5 years and below have shown very good 
efficacy confirming the usefulness of AL, there is 
concern about the sustainability of AL against 
recrudescence and prevention against re-
infection in older patients, and in areas such as 
Nigeria where prevalence of malaria 
transmission is very high with population at risk 
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of malaria being 100 % [5]. It is also not clear as 
to the duration of time for which AL will protect a 
patient from being re-infected by a new parasite 
bite.  
 
The aim of the study was to review the current 
therapeutic efficacy of AL against uncomplicated 





Study design and population 
 
This prospective study was conducted in three 
hospitals from three different Local Government 
Areas in Enugu state namely; Nsukka (District 
Hospital Nsukka), Igbo-Eze North (Bishop 
Shanahan Hospital, Enugu-Ezike), and Nkanu 
East (Cottage Hospital Ugbuawka). Enugu state 
is located in South Eastern Nigeria. Enugu is in 
the malaria endemic zone and can be 
characterized by a stable perennial transmission 
of malarial infection throughout the year [6]. This 
study was conducted from January 2012 to 
March 2013 year.  
 
One hundred and fifty four (154) patients who 
presented with symptoms compatible with acute 
uncomplicated malaria like headache and 
temperature of 37.5 ºC and above in the past two 
days, with positive malaria test and were above 6 
years were enrolled. They were all out-patients 
who had not taken any antimalarial for the past 2 
weeks. Patients who had history of serious side 
effect to the study drugs or were immune-
compromised were not enrolled. A written 
informed consent was obtained from each 
eligible participant or parents/guidance in-case of 
children prior to enrollment. Following clinical 
diagnosis by a physician, patients were given 
tablets of AL according to Table 1 [7]. 
 
Each tablet of AL contains 20 mg of artemether 
and 120 mg of lumefantrine. Since participants 
were out-patients, a compliance form designed to 
help the patient take appropriate dose at the right 
time was given to each patient along with drug 
and was submitted on the next follow up visit. 
This was used to access patient compliance. 
 
Health research ethics approval  
 
The research methods of this study were 
screened and approved by the  .  University of 
Nigeria Teaching Hospital Health Research 
Ethical Committee (UNTH-HREC) Enugu with 
approval no. NHREC / 05 / 01 / / 2008B – 
FWA00002458 – IRB00002323 and from the 
hospital administrations of each study Hospital. 
The study was carried out according to WHO 
2002 guideline [8]. 
 
Sample collection and laboratory procedure 
 
Screening was done by a Health Officer in an 
outpatient setting to identify patient’s eligibility. 
Patient’s demographic data and clinical findings 
during screening were retrieved. Finger prick 
blood was obtained for rapid malaria detection 
test whereby 3 ml of venous blood samples were 
collected in EDTA bottles from patients that 
tested positive on day 0 before treatment with 
AL. The bottles were carefully labeled and 
identified. Blood samples were transported to 
Safety Molecular Pathology Laboratory within 5 h 
of collection. Patients were then monitored and 
followed up for 28 days. The follow up blood 
samples and temperature readings were 
obtained on days 3, 7, 14 and 28 in the hospital, 
after AL treatment for molecular analysis [9].    
 
Extraction of DNA 
 
P. falciparum genomic DNA was extracted from 
blood collected in EDTA bottles by Saponin 
heamolysis [10]. The principle is that saponin 
lyses red blood cell to release malaria parasite 
which is collected by centrifugation. Boiling and 
washing helped to yield more malaria rich 
genome for PCR amplification. 
 
Plasmodium falciparum amplification and 
quantification by nested PCR 
 
A set of HPLC purified primers, were used for 
nested PCR in Applied Biosystem 2720 thermal 
cyclers (Applied Biosystems, Singapore. Serial 
No. 272S1132046). A commercially optimized 2x 
PCR master mix (Promega UK) was used in 
setting up a 25 µl reaction volume. 
Table 1: Course of artemether-lumefantrine treatment 
 
Body 
weight (kg)  
Age (years)                                        Duration (days/time) 
1 2 3 
0 h 8 h post am Pm Am pm 
5 – 14 < 3 1 tab 1 tab 1 tab 1 tab 1 tab 1 tab 
15 – 24 > 3 – 8 2 tab 2 tab 2 tab 2 tab 2 tab 2 tab 
25 – 34 > 9 – 14 3 tab 3 tab 3 tab 3 tab 3 tab 3 tab 
> 34 > 14 4 tab 4 tab 4 tab 4 tab 4 tab 4 tab 
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The first Round PCR used primers rPLU5 
forward primer 5’-CCTGTTGTTGCCTTAAAC 
TTC and rPLU6 backward primer - 5’-
TTAAAATTGTTGCAGTTAAAAC at final concen-
trations of 300 nM to amplify 1200 bp genus 
(Plasmodium) specific target of 18S ribosomal 
RNA gene. The thermal profile for first Round 
PCR was initial denaturation of 95 oC for 10 min, 
35 cycles of 94 oC for 45 s, 58 oC for 30 s, 72 oC 
for 30 s and final extension of 72 oC for 5 min.  
 
Second Round PCR reactions were set up using 
the first Round PCR product and primers - R2, 
rFAL 1 is forward primer  5’ TTAAACTGGTTT 
GGGAAAACC and rFAL 2 is backward primer 
5’ACACAATGAACTCAATCA TGA specific to P. 
falciparum for amplifying 205 bp amplicon of the 
same gene at final concentration of 400 nM in 25 
µl reaction volumes [11]. The thermal profile for 
second round PCR was initial denaturation of 95 
oC for 10 min, 35 cycles of 94 oC for 45 s, 58 oC 
for 30 s, 72 oC for 30 s, 58 oC for 30 s and final 
extension of 72 oC for 5 min. The second Round 
PCR products were visualized in 2 % agarose 
gel using SYBER Safe or Web Green (Promega 
UK, WebScientific UK).  
 
The study classified treatment responses based 
on Parasite clearance time (PCT) [12] according 
to World Health Organization (WHO) 1973 
criteria, as; Sensitive (S), Mild resistance (RI), 
Moderate resistance (RII) and Severe resistance 
(RIII) [13]. 
 
Clinical responses on day 28 were classified 
based on the WHO 2002 criteria, as: Early 
Treatment Failure (ETF), Late Clinical Failure 
(LCF), Late Parasitological Failure (LPF) or 





Data generated were summarized in Excel and 
analyzed using both Graph Pad (Prism 5) and 
SPSS (version 16). Chi test was used to 
calculate the significant differences in 
temperature. Differences in parasitic densities of 
the various groups were analyzed using ANOVA 





Patient’s demographic data 
 
Out of 160 patients enrolled, 6 were non-
compliant with medication administration and 
were excluded. 101 were female while 53 were 
males. 31 (20.1 %), 45 (29.2 %), 30 (19.4 %) and 
48 (31.1 %) were within the ages of 6 – 12 years, 
13 – 25 years, 26 – 40 years and 41 years and 




Clinical symptoms (headache and fever), 
reduced significantly with drug treatment. The 
highest body temperature was 40 ˚C while the 
least was 36.7 oC on day 0. The total number of 
patients with body temperature of between 37.1 
and 40 ˚C were 110 (71.4 %) while 44 (28.6 %) 
had body temperature of 36.7 – 37 ˚C on day 0. 
On day 3, no patients had fever of ≥ 38 ˚C but 7 
(4.8 %) had body temperature of 37.1-37.6 ˚C. 
Four (3.7) patients on day 7, had body 
temperature of 38 ˚C with headache. There was 
significant decrease in patient’s temperature from 
day 0 to day 28 (p > 0.002). The temperature 
readings on the follow up days are shown in 
Table 2. 
 
Parasiteamia density on follow-up days 
 
Out of the 154 patients sampled, 101 (78.6 %) 
were infected with Plasmodium falciparum, while 
33 (21.4 %) were not. Mean parasite densities of 
409 ± 223, 190 ± 315, 237 ± 556, 135 ± 318 and 




Table 2: Temperature readings on follow-up days 
 
Parameter  N (%) 
Day 0 Day 3 Day 7 Day 14 Day 28 
≤ 36 °C 0 29 (24.0) 46 (41.4) 56 (43.0) 54 (50.46) 
36.1–37 °C 44 (28.6) 88 (73.0) 63 (56.7) 58 (54.2) 52 (48.5) 
37.1-38 °C 65 (42.2) 4 (3.3) 1 (0.9) 3 (2.8) 1 (0.9) 
38.1-39 °C 36 (23.4) 0 4 (3.6) 0 0 
39.1-40 °C 9 (5.8) 0 0 0 0 
Total  154 121 121 121 121 
Loss to follow-up 0 7 10 14 14 
Eligibility  154 114 111 107 107 
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A comparison of the mean parasite densities on 
follow up days showed that there were significant 
decrease between day 0 and days 3,7,14 and 28 
(p < 0.001) while there were no significant 
reduction when day 3 was compared to day 7 
and day 14 compared to day 28 (p > 0.05). The 
results are shown in Table 3. 
 
Parasite clearance time  
 
The study showed that 65 (58.0 %) patients had 
delayed parasite clearance with PCT of more 
than 3 days on days 3 and 7, while 47 (42.0 %) 
had total parasite clearance on days 3 with PCT 
of ≤ 3 days and were classified as sensitive (S) 
group. Out of the 65 patients 21 (18.2 %), 22 
(19.6), and 22 (19.6 %) were classified as RI, RII 
and RIII respectively. Of the 22 patients in RIII, 4 
(6.06 %) had no change in parasite density. The 
results are shown in Table 4. 
Clinical and parasitological PCR uncorrected 
responses on day 28 post-treatment 
 
For 28 days post treatment, 14 patients were lost 
to follow up resulting to 107 (88.7 %) eligible 
patient. There was no ETF, while 4 (3.4 %), 23 
(21.4 %), and 80 (75 %) had LCF, LPF and 
ACPR. Out of the 21.4 % patients with LPF, 2.1 
% (3) did not show any response, in terms of 
parasitaemia clearance/parasitological response 
as the parasite density remained the same after 
3 days of treatment, while 16.5 % (20) of the 
population had sub-optimal response with 
decreased parasitemia density on days 3 and 7. 
Younger patients with age range between 6 and 
15 had the highest percentage (87.8 %) 
contribution to ACPR. Other age ranges and their 
contribution to each treatment group with their 
area of habitation are shown in Table 5. 
 
 












Day 0 49225 406.82±223.69 143 1475 
Day 3 23492 213.57±315.26* 0 600 
Day 7 22871 223.19±556.36*# 0 1317 
Day 14 14038 133.70±318.39* 0 1839 
Day 28 19834 190.00±371.08*# 0 1293 
*Mean difference is significance at p < 0.05 when Day 0 was compared to Days 3,7,14 and 28; #Mean difference 
is not significant at p < 0.05 when Day 3 was compared to Day 7, and Day 14 compared to Day 28 
 
   Table 4: Classification of treatment outcome based on parasite clearance time 
 
Variable Frequency (%) Classification of 
patients 
Delayed parasite clearance 65 (58.0) RI, RII, or RIII 
Total parasite clearance on day 3 without 
recurrence 
47 (42.0) S 
Parasite clearance on day 3 with recurrence 
on day 7 and 14 
21 (18.8) RI 
Decrease in parasiteamia on day 3 22 (19.6) RII 
Increase in parasiteamia on day 3 22 (19.6) RIII 
 
Table 5: Clinical and parasitological PCR uncorrected responses on days 28 post treatment 
 
Parameter  Total (%) Age (years) Residence 
  6 – 15 16 -  30 ≥ 31 Urban Rural 
No of patients 121 38 (31.4) 53 (43.8) 30 (24.8) 50 (41.3) 71 (58.7) 
Lost to follow up 14 (11.5) 5 (37.5) 5 (35.7) 4 (28.5) 10  (71.4) 4 (28.6) 
Eligibility  107 (88.4) 33 (30.8) 48 (44.8) 26 (24.3) 40 (37.4) 67 (62.6) 
ETF 0 0 0 0 0 0 
LCF 4 (3.4) 1 (3.0) 3 (6.2) 0 0 4 (6.0) 
LPF  23 (21.4) 3 (9.1) 7 (14.6) 13 (50.0) 13 (32.5) 10 (15.0) 
Total failure  27 (25.5) 4 (12.1) 10 (20.8) 13 (50.0) 13 (32.5) 14 (20.9) 
ACPR 80 (75.0) 29 (87.9) 38 (79.2) 13 (50.0) 27 (67.5) 53 (79.1) 
ACPR, adequate clinical and parasitological response; LPF, late parasitological failure; LCF, late clinical failure; 




Ayogu et al 




In 2005, Nigeria adopted artemether - 
lumefantrine as the new drug of choice for the 
treatment of uncomplicated malaria in all public 
health facilities and independent drug marketers 
(patent medicine vendors). The policy 
pronouncement was based on clinical trials 
carried out mainly with children in six Geo-
political zones in Nigerian in 2002 and 2004, and 
on the widely acclaimed efficacy of artemether – 
lumefantrine globally [14]. It is imperative to note 
that the study used outpatients and did not 
administer drugs with any fatty food. This was 
done to create a scenario that depicted what is 
obtainable in real life, as almost all patients take 
their drug after normal meal without emphasis on 
the fatty aspect of the food. This would help to 
evaluate the efficacy of the drug without bias.  
 
Patients treated in this study showed good 
responses clinically. AL was able to clear fever 
totally in a higher percentage of the patients 
while very few had sub-optimal fever clearance 
at day 3. On day 7, a lesser percentage had 
body temperature of > 38 °C with accompanying 
headache. Other follow up days maintained very 
high fever clearance. AL is known for high fever 
clearance rate and it is postulated that the rapid 
fever clearance is due to the activity of 
artemether which has a shorter half-life while the 
sustained action was by lumefantrine. The high 
fever clearance observed in this study supports 
the report of clinical trials done with children in 
Nigeria in 2002 and 2004 [14]. 
 
There is increasing evidence that parasite 
clearance time after ACT therapy is increasing in 
settings in Asia and Africa and clinical studies 
have identified delayed parasite clearance time 
as the most robust marker of artemisinin 
resistance [11, 15]. An accurate and reliable 
method for the early detection of artemisinin 
resistance has been the use of sampling multiple 
times a day at measured time points to estimate 
the rate of parasite clearance proposed [15]. 
However, this approach may be difficult to 
implement in settings of routine in vivo drug 
efficacy studies among outpatients. An 
alternative approach is to measure the 
detectable proportion of patients with 
parasitaemia after one, two or three days of the 
initiation of therapy [16,17]. Hence in this study, 
detectable proportion of patients with 
parasitaemia three days after the initiation of 
therapy was employed. Response to drug 
treatment based on parasite clearance was 
assessed using World Health Organization 
(WHO) 1973 criteria [12]. These criteria were 
used in this study because they best describe the 
nature of parasitaemia readings gotten from the 
quantitative PCR results. 
 
One third of the patient had total parasitaemia 
clearance on day 3 without recurrent parasitemia 
(sensitive). This group of patients was mainly 
younger patients indicating that AL is more 
effective in younger patients than in older 
patients.  
 
Our study showed high prevalence of patients 
with delayed parasite clearance after initiation of 
therapy suggesting emerging resistance to AL in 
the study area. Among patients with delayed 
parasite clearance, some had decreased 
parasitaemia on days 3 and 7 showing slow 
parasitaemia clearance as against rapid 
parasitaemia clearance which could arise from 
novel parasite genotypes with reduced drug 
sensitivity. Such patients will experience delayed 
recovery from malaria attack following AL 
treatment. This group of patients is not totally 
resistant to AL therapy, but is an indicator that 
reveals dwindling efficacy of AL in uncomplicated 
malaria treatment. Their pre-treatment parasite 
densities were observed to be higher than those 
obtained in the group that is sensitive to the drug. 
Our finding differs greatly from a study carried 
out with younger patients that revealed that out 
of 90 children treated with AL, 6 (6.6 %) had 
delayed PCT [18].   
 
Another group of patients showed increased 
parasitaemia level on day 3 (severe resistance). 
This implies that parasite in this group of patients 
resisted treatment and is termed parasite 
resistance, which is ability of a parasite strain to 
survive and/or multiply despite the administration 
and absorption of  drug in doses equal to or 
higher than those usually recommended but 
within the limits of tolerance of the subjects. The 
presence of parasitaemia on day 3 is most likely 
to be recrudescence than re-infection. However, 
it perhaps could be that patients with increased 
parasitemia level could have been exposed to 
new mosquito bites and had become re-infected. 
On the other hand a different school of thought 
may argue that the study drug should be able to 
protect the patient for at least 14 days post 
treatment against both re-infection and 
recrudescence. If this is true then, the presence 
of parasitaemia within this time range is 
considered as a discredit to AL therapy. With this 
observation, it has to be clearly stated as to what 
extent AL drug protects a patient after initiation 
and completion of therapy. This treatment 
response was not associated to increased 
parasite density as almost more than half of the 
patients in this group had lower pre-treatment 
parasite density compared to other groups. Of 
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great concern is the fact that all patient in this 
group except for one resulted in late 
parasitological failure.    
 
It is of paramount importance to state that a 
small percentage of patients showed no 
response as their parasite densities remained the 
same at day 3 revealing another group that is 
resistant to AL and had late parasitological failure 
even though there were no danger signs of 
severe malaria in them. A phenomenon that 
could lead to this observation suggesting 
artemisinin resistance is an increased propensity 
for these parasites to form “dormant” (or 
quiescent) rings under artemisinin exposure 
[19,20]. Parasites under this condition still avert 
the activities of AL even when correct dosage is 
given. This could be the possible explanation for 
the above abnormality in parasitemia density 
post treatment with AL in this study. 
 
We observed that even though some of the 
patients showed sub optimal response and 
resistance to AL treatment, we did not record any 
early treatment failure or late clinical failure as 
most patients with increased parasitemia level, 
post treatment, were asymptomatic. This could 
be explained by the fact that the study area - 
Enugu South East Nigeria is situated in a malaria 
endemic area with high transmission rate thereby 
exposing individuals to high parasite load. 
 
This study showed a low ACPR of 75 %, PCR 
uncorrected, at 28 days post treatment, 3.4 % 
had LCF while 21.4 % patients had LPF. One 
likely reason for this low ACPR could be not 
involving genotyping to differentiate between 
recrudescence and re-infection. It perhaps could 
mean that patients with increased parasitemia 
level could have been exposed to new mosquito 
bites and had become re-infected. Other factors 
that may be responsible for the low therapeutic 
efficacy observed in this study are; first, 
participants were 70 % adult but children give 
better therapeutic response than adults. 
Secondly, it could arise from poor lumefantrine 
absorption as oral bioavailability of lumefantrine 
has been shown to be considerably reduced 
during the acute phase of malaria and also to 
vary from one individual to another [21]. Lastly, 
there is emerging resistance developing towards 
(AL) by Plasmodium falciparum, in Enugu State, 
South Eastern Nigeria. This agrees with a clinical 
report from Africa [22] and a study done in Enugu 
State, South Eastern Nigeria [23] showing 
reduced efficacy of AL in parasitemia clearance. 
This observation could be attributed to some 
genetic variations like mutations, single 
nucleotide polymorphisms (SNPs) and copy 
number variation (CNV) in plasmodial genes 
leading to AL resistance with significant decrease 
in plasmodial sensitivity. 
 
Limitations of the study 
 
This study has some limitations and the results 
were interpreted as such. The study did not 
differentiate recrudescence from re-infection, 
hence LCF, LPF and ACPR were uncorrected 
responses. The study used patients > 5 years of 
age. The study also used outpatients who took 
their medications at home, and therefore, strict 
adherence to the recommended dosage regimen 




Although it is encouraging to observe rapid fever 
elimination following the use of AL therapy for 
patients with uncomplicated malaria in Enugu 
State, Nigeria, there was increase in parasite 
clearance time and high frequency of late 
parasitological failures among the patients, 
indicating reduction in the therapeutic efficacy of 
the combination therapy. Since AL has been 
adopted as the first-line treatment for 
uncomplicated malaria in Nigeria’s National 
Antimalarial Treatment Policy, government, 
policy-makers and researchers should focus on 
development and implementation of policies, 
strategies and interventions that will prevent the 
development of resistance to AL therapy in order 
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